정상여성 및 자궁경부암 환자에서 HSV-II중화항체 = Herpes Virus Type II Neutralizing Antibody in Normal Women and Patients with Cervical Cancer

다국어 초록 (Multilingual Abstract)

In order to observe the relationship between cervical cancer and HSV-II infection, we performed this study on the subjects consisting of 51 normal women, 29 non-invasive and 49 invasive cervical cancer patients. Distrbution and titer of HSV-II neutralizing antibody in sera of subjects were measured by in vitro doubling-dilution neutralizing test. The following results were obtained. 1. HSV-II neutralizing antibody showed more positives in non-invasive and invasive cervical cancer patients when compared with control group as 18/29 cases(62.1%) in non-invasive and 42/49 cases(85.7%) in invasive cervical cancer and 12/51 cases(23.5%) in control group. Distribution of HSV-II neutralizing antibody showed more increased tendency as progressing of clinical stage. 2. Distribution of HSV-II neutralizing antibody by age showed gradual increase from 31 years and peak at 41-60 years in all cases. 3. Titer of HSV-II neutralizing antibody was lower than 1:64 in control group. On the other hand, titer of HSV-II neutralizing antibody was higher as progressing cervical cancer and was higher than 1:128 in invasive cervical cancer patients. From the above results, it is thought that HSV-II is one of etiological factors of cervical cancer.